References
- Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol 64, 384–389, 2006.10.1111/j.1365-2265.2006.02473.x16584509
- Behan L, Kelleher G, Hannon MJ, Brady JJ, Rogers B, Tormey W, et al. Low dose hydrocortisone replacement therapy is associated with improved bone remodeling balance in hypopituitary male patients. Eur J Endocrinol 170, 141–150, 2013.10.1530/EJE-13-059624123094
- Bensing S, Hulting AL, Husebye ES, Kampe O, Lovas K. Epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur J Endocrinol 175, 107–116, 2016.10.1530/EJE-15-124227068688
- Bentivegna G, Osella G, Pia A, Terzolo M. Effects on bone health of glucocorticoid replacement therapy in primary and secondary adrenal insufficiency: A review. Curr Opinion Endocr Metab Res 3, 31–37, 2018.10.1016/j.coemr.2018.02.008
- Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 101, 364–389, 2016.10.1210/jc.2015-1710488011626760044
- Braatvedt GD, Joyce M, Evans M, Clearwater J, Reid IR. Bone mineral density in patients with treated Addison’s disease. Osteoporos Int 10, 435–440, 1999.10.1007/s00198005025110663342
- Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 86, 1968–1972, 2001.10.1210/jcem.86.5.748311344193
- Camozzi V, Betterle C, Frigo AC, Zaccariotto V, Zaninotto M, De Caneva E, Lucato P, Gomiero W, Garelli S, Sabbadin C, Salva M, Costa MD, Boscaro M, Luisetto G. Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59, 319–329, 2018.10.1007/s12020-017-1380-828795340
- Chihaoui M, Yazidi M, Chaker F, Belouidhnine M, Kanoun F, Lamine F, Ftouhi B, Sahli H, Slimane H. Bone mineral density in Sheehan’s syndrome; prevalence of low bone mass and associated factors. J Clin Densitom 19, 413–418, 2016Chikada N, Imaki T, Hotta M, Sato K, Takano K. An assessment of bone mineral density in patients with Addison’s disease and isolated ACTH deficiency treated with glucocorticoid. Endocr J 51, 355–360, 2004.10.1016/j.jocd.2016.02.00226993664
- Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20, 843–851, 2009.10.1007/s00198-009-0838-919190842
- Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metabol 93, 400–409, 2008.10.1210/jc.2007-1134
- Holick MF. Vitamin D deficiency. N Engl J Med 357, 266–281, 2007.10.1056/NEJMra070553
- Jodar E, Valdepenas MPR, Martinez G, Jara A, Hawkins F. Long-term follow-up of bone mineral density in Addison’s disease. Clin Endocrinol 58, 617–620, 2003.10.1046/j.1365-2265.2003.01761.x
- Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low dose glucocorticoid replacement therapy. J Clin Endocrinol Metabol 97, 85–92, 2012.10.1210/jc.2011-2036
- Lovas K, Gjesdal CG, Christensen M, Wolff AB, Almas B, Svartberg J, Fougner KJ, Syversen U, Bollerslev J, Falch JA, Hunt PJ, Chatterjee VK, Husebye ES. Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol 160, 993–1002, 2009.10.1530/EJE-08-0880
- Meddeb N, Sahli H, Chahed M, Abdelmoula J, Feki M, Salah H, Frini S, Kaabachi N, Belkahia Ch, Mbazaa R, Zouari B, Sellami S. Vitamin D deficiency in Tunisia. Osteoporos Int 16, 180–183, 2005.10.1007/s00198-004-1658-6
- Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, Weetman AP. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol 46, 255–261, 1997.10.1046/j.1365-2265.1997.780907.x
- Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 843, 1–129, 1994.
- Schulz J, Frey KR, Cooper MS, Zopf K, Ventz M, Diederich S, Quinkler M. Reduction in daily HC dosage improves bone health in primary adrenal insufficiency. Eur J Endocrinol (Oxf) 174, 531–538, 2016.10.1530/EJE-15-1096
- Valero MA, Leon M, Ruiz Valdepenas MP, Larrodera L, Lopez MB, Papapietro K, Jara A, Hawkins F. Bone density and turnover in Addison’s disease: effect of glucocorticoid treatment. Bone Miner 26, 9–17, 1994.10.1016/S0169-6009(08)80158-4
- Weinstein RS. Glucocorticoid-induced bone disease. N Engl J Med 365, 62–70, 2011.10.1056/NEJMcp101292621732837
- Zelissen PMJ, Croughs R, Van Rijk P, Raymakers A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120, 207, 1994.10.7326/0003-4819-120-3-199402010-000058273983